Breast Cancer Research and Treatment

, Volume 127, Issue 3, pp 813–818 | Cite as

Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis

  • Ping Zhou
  • Liang-Feng Du
  • Guo-Qiang Lv
  • Xian-Ming Yu
  • Yuan-Long Gu
  • Jian-Ping Li
  • Chun Zhang


The matrix metalloproteinases (MMP) can degrade various components of the extracellular matrix and its functional genetic polymorphisms may be associated with breast cancer risk. However, this relationship remains controversial. A meta-analysis was conducted in order to investigate the potential association between four polymorphisms in the MMP gene and breast cancer risk. A database search yielded a total of 9 studies involving 2,597 cases and 2,618 controls. Four polymorphisms were included in the meta-analysis: MMP-1 −1607 2G/1G (rs1799750), MMP-2 −1306 C/T (rs243865), MMP-3 −1171 6A/5A (rs3025058) and MMP-9 −1562 C/T (rs3918242). Crude odds ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of association. When all the studies were pooled into the meta-analysis, we found that breast cancer cases had a significantly higher frequency of CC genotype (OR = 1.27, 95% CI = 1.10, 1.47; P = 0.001) and lower frequency of CT genotype (OR = 0.78, 95% CI = 0.67, 0.91; P = 0.001) of MMP-2. No significant difference was found in any genotype of MMP-1, MMP-3 or MMP-9. In conclusion, this meta-analysis suggested that MMP-2 −1306 C/T polymorphism may contribute to breast cancer susceptibility. More studies were needed especially in Asians in the future.


Matrix metalloproteinases Breast cancer Polymorphism Meta-analysis 


Conflict of interest

The authors declare that they have no conflict of interests.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065PubMedCrossRefGoogle Scholar
  3. 3.
    Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776PubMedCrossRefGoogle Scholar
  4. 4.
    Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800PubMedCrossRefGoogle Scholar
  5. 5.
    Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8(10):843–854PubMedGoogle Scholar
  6. 6.
    Gross J, Lapiere CM (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 48:1014–1022PubMedCrossRefGoogle Scholar
  7. 7.
    Lohi J, Wilson CL, Roby JD, Parks WC (2001) Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 276(13):10134–10144PubMedCrossRefGoogle Scholar
  8. 8.
    Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8):827–839PubMedCrossRefGoogle Scholar
  9. 9.
    Peng B, Cao L, Ma X, Wang W, Wang D, Yu L (2010) Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 25(4):371–379PubMedCrossRefGoogle Scholar
  10. 10.
    Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, Zhang Z, Wang X, Yu L (2010) Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case–control studies. Mutagenesis 25(1):41–48PubMedCrossRefGoogle Scholar
  11. 11.
    McColgan P, Sharma P (2009) Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 125(6):1473–1478PubMedCrossRefGoogle Scholar
  12. 12.
    Decock J, Paridaens R, Ye S (2008) Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 73(3):197–211PubMedCrossRefGoogle Scholar
  13. 13.
    Tower GB, Coon CI, Brinckerhoff CE (2003) The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res Treat 82(2):75–82PubMedCrossRefGoogle Scholar
  14. 14.
    Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88(3):197–204PubMedCrossRefGoogle Scholar
  15. 15.
    Decock J, Long JR, Laxton RC, Shu XO, Hodgkinson C, Hendrickx W, Pearce EG, Gao YT, Pereira AC, Paridaens R, Zheng W, Ye S (2007) Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res 67(21):10214–10221PubMedCrossRefGoogle Scholar
  16. 16.
    Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, Jones JL (2007) Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 13(22 Pt 1):6673–6680PubMedCrossRefGoogle Scholar
  17. 17.
    Beeghly-Fadiel A, Shu XO, Long J, Li C, Cai Q, Cai H, Gao YT, Zheng W (2009) Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer 124(1):208–214PubMedCrossRefGoogle Scholar
  18. 18.
    Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J (2006) Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 95(1):65–72PubMedCrossRefGoogle Scholar
  19. 19.
    Beeghly-Fadiel A, Cai Q, Lu W, Long J, Gao YT, Shu XO, Zheng W (2009) No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 18(4):1324–1327PubMedCrossRefGoogle Scholar
  20. 20.
    Beeghly-Fadiel A, Lu W, Long JR, Shu XO, Zheng Y, Cai Q, Gao YT, Zheng W (2009) Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 18(6):1770–1776PubMedCrossRefGoogle Scholar
  21. 21.
    Beeghly-Fadiel A, Lu W, Shu XO, Long J, Cai Q, Xiang Y, Gao YT, Zheng W (2010) MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Res Treat doi: 10.1007/s10549-010-1119-1
  22. 22.
    Beeghly-Fadiel A, Long JR, Gao YT, Li C, Qu S, Cai Q, Zheng Y, Ruan ZX, Levy SE, Deming SL, Snoddy JR, Shu XO, Lu W, Zheng W (2008) Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res 68(15):6453–6459PubMedCrossRefGoogle Scholar
  23. 23.
    Shin A, Cai Q, Shu XO, Gao YT, Zheng W (2005) Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 7(4):R506–R512PubMedCrossRefGoogle Scholar
  24. 24.
    Shagisultanova EI, Novikova IA, Sidorenko YS, Marchenko GN, Strongin AY, Malkhosyan SR (2004) The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res 24(1):199–201PubMedGoogle Scholar
  25. 25.
    Lei H, Zaloudik J, Vorechovsky I (2002) Lack of association of the −1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem 48(5):798–799PubMedGoogle Scholar
  26. 26.
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R (2002) A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8(12):3820–3823PubMedGoogle Scholar
  27. 27.
    Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25(3):399–404PubMedCrossRefGoogle Scholar
  28. 28.
    Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J (2004) An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 23(1):121–125PubMedGoogle Scholar
  29. 29.
    Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Koppel H, Leithner A, Wascher TC, Paulweber B, Samonigg H (2004) The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res 10(10):3518–3520PubMedCrossRefGoogle Scholar
  30. 30.
    Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P, Forsti A (2007) Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103(1):61–69PubMedCrossRefGoogle Scholar
  31. 31.
    Roehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS (2007) Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 102(1):123–124PubMedCrossRefGoogle Scholar
  32. 32.
    Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL (2007) Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9(5):R67PubMedCrossRefGoogle Scholar
  33. 33.
    Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, Bautista-Lam JR, Andrade-Soto M, Jonguitud-Olguin G, Rodriguez-Hernandez A, Anaya-Ventura A, Baltazar-Rodriguez LM, Orozco-Ruiz M, Soriano-Hernandez AD, Rodriguez-Sanchez IP, Lugo-Trampe A, Espinoza-Gomez F, Michel-Peregrina ML (2008) Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 65(1):68–72PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang Z, Wang M, Wu D, Tong N, Tian Y (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies. Breast Cancer Res Treat 120(2):509–517PubMedCrossRefGoogle Scholar
  35. 35.
    Zhang J, Qiu LX, Wang ZH, Wu XH, Liu XJ, Wang BY, Hu XC (2010) MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls. Breast Cancer Res Treat 123(2):549–555PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC (2010) NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 123(3):877–883PubMedCrossRefGoogle Scholar
  37. 37.
    Yao L, Qiu LX, Yu L, Yang Z, Yu XJ, Zhong Y, Hu XC (2010) The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects. Breast Cancer Res Treat 123(1):227–231PubMedCrossRefGoogle Scholar
  38. 38.
    Wang Z, Fu Y, Tang C, Lu S, Chu WM (2010) SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat 122(1):193–198PubMedCrossRefGoogle Scholar
  39. 39.
    Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Mutlu F, Alatas F (2009) The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test Mol Biomarkers 13(5):671–678PubMedCrossRefGoogle Scholar
  40. 40.
    Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W (2005) A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131(1):19–25PubMedCrossRefGoogle Scholar
  41. 41.
    Hettiaratchi A, Hawkins NJ, McKenzie G, Ward RL, Hunt JE, Wakefield D, Di Girolamo N (2007) The collagenase-1 (MMP-1) gene promoter polymorphism −1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer 96(5):783–792PubMedCrossRefGoogle Scholar
  42. 42.
    Yi YC, Chou PT, Chen LY, Kuo WH, Ho ES, Han CP, Yang SF (2010) Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. Clin Chem Lab Med 48(3):337–344PubMedCrossRefGoogle Scholar
  43. 43.
    Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R (2003) A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200(1):49–55PubMedCrossRefGoogle Scholar
  44. 44.
    Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRefGoogle Scholar
  45. 45.
    Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549–7558PubMedCrossRefGoogle Scholar
  46. 46.
    Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N (2009) Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 125(2):131–151PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Ping Zhou
    • 1
    • 2
  • Liang-Feng Du
    • 1
  • Guo-Qiang Lv
    • 2
  • Xian-Ming Yu
    • 2
  • Yuan-Long Gu
    • 2
  • Jian-Ping Li
    • 2
  • Chun Zhang
    • 2
  1. 1.Department of Intensive Care UniteThe Third Affiliated Hospital to Nantong UniversityWuxiChina
  2. 2.Department of General SurgeryThe Third Affiliated Hospital to Nantong UniversityWuxiChina

Personalised recommendations